Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 5/20 | 1.00 |
| ▸ | CA12 | O43570 | 6/20 | 0.58 |
| ▸ | CA1 | P00915 | 6/20 | 0.58 |
| ▸ | CA2 | P00918 | 6/20 | 0.58 |
| ▸ | CA9 | Q16790 | 5/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PLK1 | P53350 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30837827 | 1.00 | PDE7A (1.00) | PDE7ACA12CA1CA2CA9 | |
| SCHEMBL31597397 | 0.81 | CA12 (0.70) | PDE7ACA12CA1CA2CA9 | |
| SCHEMBL18239972 | 0.79 | HTT (0.67) | PDE7ACA12CA1CA2CA9 | |
| SCHEMBL16319969 | 0.77 | PDE7A (0.63) | PDE7ACA12CA1CA2CA9 | |
| SCHEMBL3334533 | 0.77 | PDE7A (0.69) | PDE7ACA12CA1CA2CA9 | |
| SCHEMBL30837780 | 0.77 | PDE7A (0.69) | PDE7ACA12CA1CA2CA9 | |
| SCHEMBL30837960 | 0.76 | PDE7A (1.00) | PDE7ACA12CA1CA2CA9 | |
| SCHEMBL3336461 | 0.76 | PDE7A (1.00) | PDE7ACA12CA1CA2CA9 | |
| SCHEMBL15231061 | 0.75 | CA12 (0.72) | PDE7ACA12CA1CA2CA9 | |
| SCHEMBL31597447 | 0.75 | PDE7A (0.70) | PDE7ACA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9192610-B2 | Use of quinazoline derivatives for neurodegenerative diseases | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2015-11-24 | — | — | US | claimed |
| EP-2433637-B9 | USE OF QUINAZOLINE DERIVATIVES FOR NEURODEGENERATIVE DISEASES | CONSEJO SUPERIOR INVESTIGACION (ES) | 2015-06-10 | — | — | EP | claimed |
| EP-2433637-B1 | USE OF QUINAZOLINE DERIVATIVES FOR NEURODEGENERATIVE DISEASES | CONSEJO SUPERIOR INVESTIGACION (ES) | 2014-06-11 | — | — | EP | claimed |
| US-20120129877-A1 | USE OF QUINAZOLINE DERIVATIVES FOR NEURODEGENERATIVE DISEASES | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2012-05-24 | — | — | US | claimed |
| EP-2433637-A1 | USE OF QUINAZOLINE DERIVATIVES FOR NEURODEGENERATIVE DISEASES | Consejo Superior de Investigaciones Científicas (CSIC) (ES) | 2012-03-28 | — | — | EP | claimed |
| US-20100152213-A1 | COMPOUND THAT IS A DUAL INHIBITOR OF ENZYMES PDE7 AND/OR PDE4, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2010-06-17 | — | — | US | claimed |
| EP-2130823-A1 | COMPOUND THAT IS A DUAL INHIBITOR OF ENZYMES PDE7 AND/OR PDE4, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Consejo Superior De Investigaciones Científicas (ES) | 2009-12-09 | — | — | EP | claimed |
| US-20260060970-A1 | Use of a Therapeutic Agent with Phosphodiesterase-7 Inhibitory Activity for the Treatment and Prevention of Diseases Associated with Chronic Fatigue, Exhaustion and/or Exertional Intolerance | MITODICURE GMBH (DE) | 2026-03-05 | — | — | US | disclosed |
| US-9192610-B2 | Use of quinazoline derivatives for neurodegenerative diseases | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2015-11-24 | — | — | US | disclosed |
| EP-2433637-B9 | USE OF QUINAZOLINE DERIVATIVES FOR NEURODEGENERATIVE DISEASES | CONSEJO SUPERIOR INVESTIGACION (ES) | 2015-06-10 | — | — | EP | disclosed |
| EP-2433637-B1 | USE OF QUINAZOLINE DERIVATIVES FOR NEURODEGENERATIVE DISEASES | CONSEJO SUPERIOR INVESTIGACION (ES) | 2014-06-11 | — | — | EP | disclosed |
| US-20120129877-A1 | USE OF QUINAZOLINE DERIVATIVES FOR NEURODEGENERATIVE DISEASES | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2012-05-24 | — | — | US | disclosed |
| EP-2433637-A1 | USE OF QUINAZOLINE DERIVATIVES FOR NEURODEGENERATIVE DISEASES | Consejo Superior de Investigaciones Científicas (CSIC) (ES) | 2012-03-28 | — | — | EP | disclosed |
| US-20100152213-A1 | COMPOUND THAT IS A DUAL INHIBITOR OF ENZYMES PDE7 AND/OR PDE4, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2010-06-17 | — | — | US | disclosed |
| US-20100152213-A1 | COMPOUND THAT IS A DUAL INHIBITOR OF ENZYMES PDE7 AND/OR PDE4, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2010-06-17 | — | — | US | disclosed |
| US-20100152213-A1 | COMPOUND THAT IS A DUAL INHIBITOR OF ENZYMES PDE7 AND/OR PDE4, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2010-06-17 | — | — | US | disclosed |
| EP-2130823-A1 | COMPOUND THAT IS A DUAL INHIBITOR OF ENZYMES PDE7 AND/OR PDE4, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Consejo Superior De Investigaciones Científicas (ES) | 2009-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260060970-A1 | Use of a Therapeutic Agent with Phosphodiesterase-7 Inhibitory Activity for the Treatment and Prevention of Diseases Associated with Chronic Fatigue, Exhaustion and/or Exertional Intolerance | PDE5A, PDE4C, PDE12 | PDE7A 5/4885CA12 1376/4885CA1 2358/4885 |
| US-20120129877-A1 | USE OF QUINAZOLINE DERIVATIVES FOR NEURODEGENERATIVE DISEASES | PARK7, SNCA, NLN | PDE7A 867/4885CA12 4698/4885CA1 3543/4885 |
| US-20100152213-A1 | COMPOUND THAT IS A DUAL INHIBITOR OF ENZYMES PDE7 AND/OR PDE4, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | PDE4B, PDE7B, PDE12 | PDE7A 6/4885CA12 1678/4885CA1 1199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.